Novo Nordisk Shares Plunge as Alzheimer’s Trial Fails

Investor optimism for a breakthrough Alzheimer’s treatment from Novo Nordisk has evaporated following disappointing clinical trial results. The pharmaceutical giant’s attempt to demonstrate that its semaglutide compound—the active ingredient behind blockbuster drugs Ozempic and Wegovy—could slow cognitive decline in early-stage Alzheimer’s patients has ended in failure, sending shares tumbling to multi-year lows.

The EVOKE studies, whose results were highly anticipated by markets, failed to achieve their main objective. While Novo Nordisk reported some improvement in specific biomarkers, the treatment did not demonstrate meaningful clinical benefit for patients. This outcome prompted the company to cancel planned extensions of the research program.

Martin Holst Lange, head Read more...